Pharmaceutical firm Biocon will announce its third quarter (October-December) earnings on Wednesday. Analysts on an average expect 19 percent growth in profit after tax of Rs 109.6 crore and 20 percent growth in revenue at Rs 759 crore compared to a year ago period, according to CNBC-TV18 poll.
Analysts are not factoring in any licensing income in the quarter gone by, which was Rs 3 crore in September quarter.
Core sales growth of 20 percent will be led by biopharma, India formulations and CRAMS business, analysts say, adding Biopharma will be lead by immunosuppressants (Serolimus) and insulin in emerging markets.
Year-on-year growth in earnings before interest, tax, depreciation and amortisation is expected to be 22 percent at Rs 174 crore compared to a year ago period. M
Operating profit margin may expand 50 basis points to 22.9 percent on account of contract research and manufacturing services (CRAMS) business. They expect earnings before interest and tax in CRAMS between 30-35 percent.
IN-105 progress or launch, Herceptin launch in India and Serolimus launch in US will be key factors to watch out for.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
